New antibiotic to combat deadly bacte... - Lung Conditions C...

Lung Conditions Community Forum

56,245 members66,871 posts

New antibiotic to combat deadly bacterial ‘superbugs’ enters clinical trials

2greys profile image
3 Replies

In a critical step towards addressing an urgent unmet medical need due to infections caused by antibiotic-resistant bacteria - also known as ‘superbugs’ - a new antibiotic (QPX9003) discovered by Monash University researchers has entered Phase 1 clinical trials in the United States.

The trials have been initiated by the US-based biopharmaceutical company Qpex Biopharma Inc. (Qpex) who have worked in collaboration with Monash to drive clinical development of the drug.

QPX9003, which was discovered at the Monash Institute of Pharmaceutical Sciences (MIPS) and the Monash Biomedicine Discovery Institute (BDI), is an intravenously-administered synthetic next-generation polymyxin for treating Gram-negative ‘superbug’ infections. No new polymyxins have been approved since polymyxin B and colistin became available in the late 1950s.

Deemed a global health crisis, Gram-negative bacteria can cause serious infections, including pneumonia, bloodstream infections, urinary tract infections, peritonitis and meningitis. The World Health Organization has highlighted that new antibiotics are urgently needed to treat bacterial ‘superbugs’, which have the potential to kill 10 million people per year by 2050 – more than any other type of disease.

monash.edu/news/articles/ne...

Written by
2greys profile image
2greys
To view profiles and participate in discussions please or .
Read more about...
3 Replies
RoadRunner44 profile image
RoadRunner44

Thank goodness for the researchers and their findings. This is a big step forward.

Fingers crossed for this - we’ve been increasingly hampered by a cephalosporin allergy. The two most recent pseudomonas targeted antibiotics for MDR strains (ceftolozane-tazobactam and ceftazidime-avibactam) are both cephalosporin based, and desensitisation is both hugely time consuming and massively impractical for multiple courses. Not to mention not always successful. A new polymyxin would be a major boost.

teenieleek profile image
teenieleek

This is good news because pharmaceutical companies have for decades been unwilling to invest in the research needed to create new antibiotics because of the potentially low return. Things like viagra were much more lucrative so that’s where the investment went.

Not what you're looking for?

You may also like...

How to access clinical trials.

Hi Everybody I hope everyone is feeling well today - a liitle humid and warm here in Liverpool...
Jo_BLFHelpline profile image
British Lung Foundation

Yep B4 You Say It B12 Again ... But This Time Scientists Unravel B12 / GA 101 Secrets

Yumi Al Have To ..... Please :O Vitamin Microbiology could combat cancer as professor martin warren...

Honey

Honey, that delectable condiment for breads and fruits, could be one sweet solution to the serious,...
martin1945 profile image

Article list.

The devil's tic tacks well and truly kicked in. Vertigo, from left ear damage, perforated ear drum,...
2greys profile image

Keep taking the tablets

After last week's story that people should stop taking their abs when they feel better there has...

Moderation team

See all
AsthmaandLung profile image
AsthmaandLungAdministrator
moderator_AandLUK profile image
moderator_AandLUKAdministrator
Claire_ALUK profile image
Claire_ALUKAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.